EBS:NYE-Emergent Biosolutions Inc. (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | New York Stock Exchange

Last Closing

USD 11.77

Change

0.00 (0.00)%

Market Cap

USD 1.16B

Volume

2.17M

Analyst Target

USD 112.29
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Emergent BioSolutions Inc is a specialty biopharmaceutical company It develops, manufactures, and delivers a portfolio of medical countermeasures for government agencies in the areas of biological and chemical threats and emerging infectious diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-10 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

-2.19 (-1.24%)

USD 79.77B
TAK Takeda Pharmaceutical Co Ltd A..

-0.11 (-0.81%)

USD 45.03B
HLN Haleon plc

-0.23 (-2.42%)

USD 43.99B
RDY Dr. Reddy’s Laboratories Ltd..

-0.23 (-1.53%)

USD 12.67B
CTLT Catalent Inc

-0.21 (-0.35%)

USD 10.78B
ELAN Elanco Animal Health

-0.15 (-1.05%)

USD 6.96B
BHC Bausch Health Companies Inc

-0.22 (-2.35%)

USD 3.44B
AMRX Amneal Pharmaceuticals, Inc. C..

+0.05 (+0.54%)

USD 2.86B
CPHI China Pharma Holdings Inc

N/A

USD 3.43M
YCBD cbdMD Inc

+0.03 (+5.96%)

USD 1.73M

ETFs Containing EBS

XB4A:F Xtrackers ATX UCITS ETF 1.. 19.81 % 0.00 %

-0.92 (-1.93%)

USD 0.04B
XB4A:XETRA Xtrackers ATX UCITS ETF 1.. 19.81 % 0.00 %

-1.30 (-1.93%)

USD 0.05B
EXXX:XETRA iShares ATX UCITS ETF (DE.. 19.51 % 0.00 %

-0.70 (-1.93%)

USD 0.09B
EBNK:CA Evolve European Banks Enh.. 5.06 % 0.00 %

-0.22 (-1.93%)

CAD 3.94M
IS3H:XETRA iShares MSCI EMU Mid Cap .. 1.83 % 0.00 %

-1.14 (-1.93%)

USD 0.13B
EMUM:SW iShares MSCI EMU Mid Cap .. 1.83 % 0.00 %

N/A

USD 0.13B
LDEG:LSE L&G Quality Equity Divide.. 1.30 % 0.00 %

-15.20 (-1.93%)

N/A
FEUZ:LSE First Trust Eurozone Alph.. 1.21 % 0.00 %

-40.00 (-1.93%)

USD 0.06B
FEUD:LSE First Trust Eurozone Alph.. 1.21 % 0.00 %

-38.25 (-1.93%)

USD 0.02B
LDEU:LSE L&G Quality Equity Divide.. 1.13 % 0.00 %

-0.25 (-1.93%)

USD 0.04B
EUMD:LSE iShares MSCI Europe Mid C.. 1.04 % 0.00 %

-0.14 (-1.93%)

USD 0.26B
EL43:XETRA Deka MSCI Europe MC UCITS.. 0.96 % 0.00 %

-0.25 (-1.93%)

USD 0.02B
PRFZ Invesco FTSE RAFI US 1500.. 0.00 % 0.39 %

-0.62 (-1.93%)

USD 2.56B
IS3H:F iShares IV Public Limited.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 390.42% 87% B+ 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 390.42% 87% B+ 95% A
Trailing 12 Months  
Capital Gain 488.50% 87% B+ 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 488.50% 87% B+ 96% N/A
Trailing 5 Years  
Capital Gain -78.73% 14% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -78.73% 14% F 5% F
Average Annual (5 Year Horizon)  
Capital Gain -29.19% 7% C- 1% F
Dividend Return -29.19% 7% C- 1% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 74.53% 27% F 12% F
Risk Adjusted Return -39.17% 20% F 7% C-
Market Capitalization 1.16B N/A N/A N/A N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 29.40 N/A N/A
Price/Book Ratio N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A
Price/Free Cash Flow Ratio N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A
Return on Invested Capital N/A N/A N/A
Return on Assets N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector